Vol. 7, No. 1: January 2008 – EXECUTIVE SUMMARY
Welcome to this issue of Pharma Marketing News. Subscribe Now to get the current and future issues FREE!
Order and pay for this ENTIRE ISSUE now using your credit card…
ONLY $12.95Download PDF file immediately after paying:
]]>
CONTENTS
- OpEd: DTC User Fees Go PDUffft!
(www.news.pharma-mkting.com/pmn71-Jan08-oped.htm) - Use of Celebrities for PR and DTC Advertising
- Pharma Marketing Network 2007 Report
- Wither CME?
- Is It Time to End Industry Sponsored CME?
- Cholesterol Drug Users Discuss Their Medication
Article Summaries
Use of Celebrities for PR and DTC Advertising
“Break a Leg,” But Avoid Pratfalls!
Congress is investigating the use of celebrity endorsements in pharmaceutical advertising and recently sent a letter to Pfizer questioning if the use of Dr. Robert Jarvik, a physician and inventor of the Jarvik artificial heart, is misleading consumers. At issue is the fact that Jarvik has never held a license to practice medicine in any state.
If you have questions about the “dos & don’ts” and “pros & cons” of using medical and non-medical mouthpieces for pharma PR and DTC advertising, this article may have some answers based on interviews of experts with years of experience in this area.
Topics and issues covered include:
- Celebrity Endorsements: Clear and Prominent Disclosure
- Congress Probes Celebrities
- When Celebrities Go Bad
- Prepare Your Celebrities for Media Interviews
- Bloggers Weigh In on Montel and Jarvik
- Includes comments from Pharma Marketing Roundtable members
Order and pay for this reprint now using your credit card…
ONLY $6.95Download PDF file immediately after paying:
]]>
Pharma Marketing Network 2007 Report
Stats and Subscriber Profiles
Pharma Marketing Network is a leading online resource for pharmaceutical marketers, bringing together into a single online community pharmaceutical marketing, advertising, and sales professionals from pharmaceutical companies, communications companies, and marketing service providers.
The Pharma Marketing News newsletter is the linchpin of the Network, which also includes an online discussion and social networking Forum site (see “An Online Community of Our Own“), Pharma Marketing Blog, and an informational Web portal site packed with resources for marketers.
This report provides information about our subscribers and Web site statistics for 2007.
Topics and issues covered include:
- Pharma Marketing News: Types of articles, subscriber profile
- Portal Site: Subdomains, site statistics
- Pharma Marketing Network Forums: site statistics
- Pharma Marketing Blog: Reader survey results, statistics
- Pharma Marketing Talk
- Pharma Marketing Vendor Directory
FREE Full-Text Reprint Available
Click Here for PDF File.
Wither CME?
New Rules for Industry Support
Last year, the pharmaceutical industry provided $1.19 billion to sponsor CME programs ($1.44 billion if you include advertising and exhibits at CME events). That’s about 60% of all sources of funding for CME reported by ACCME.
A task force of the American Psychological Association (APA) recently recommended that its 148,000 members “turn their nose up at pharma funds; limit the role industry plays at professional conferences, meetings and CME sessions; and adopt strict guidelines on conflict-of-interest disclosure.”
Congress continues to examine pharma industry support of CME and ACCME has issued some new guidance for accredited CME providers.
This article examines the current state of industry support for CME and what reforms may be coming down the pike.
Topics and issues covered include:
- Impact on MECCs
- Influence Within Medical Schools
- What About Physician Societies?
- Fixing the “Problem”
- Virtually Free CME?
- The CME Evolutionary Horizon
Order and pay for this reprint now using your credit card…
ONLY $9.95Download PDF file immediately after paying:
]]>
Is It Time to End Industry Sponsored CME?
Survey Results
Since 17 December 2007, Pharma Marketing News has hosted an online survey (access it here) asking respondents their views regarding industry sponsorship of accredited CME, including views on value, bias, ACCME firewalls, and alternative means of CME support. We present some preliminary results in this summary.
Topics and issues covered include:
- About Respondents
- Views on Industry-Sponsored CME
- Views of Segments: Accredited Organizations and Pharmacos
FREE Full-Text Reprint Available
Click Here for PDF File.
Cholesterol Drug Users Discuss Their Medication
Talking Health at a Local Coffee Shop
At breakfast recently in one of his favorite coffee shops, Jim Avery, professor of advertising at the University of Oklahoma, was talking with some friends who he knew had some health problems. Avery mentioned that there were a couple of recent articles in newspapers on cholesterol drugs and clinical trials. No one had seen or even heard of these articles and Avery was a bit taken aback that he was the only one who had seen what he judged to be fairly important information on healthcare.
Avery took the opportunity to turn the breakfast meeting into a little impromptu focus group. This article summarizes what he learned.
Topics and issues covered include:
- Cholesterol Treatment in the News
- Surprising Lack of Trust
- Should I Stop Taking Zetia?
- Surrogate Endpoints “Miss the Point”
- FDA Not Doing Its Job?
Order and pay for this reprint now using your credit card…
ONLY $4.95Download PDF file immediately after paying:
]]>
